Novartis AG (ADR)  

(Public, NYSE:NVS)   Watch this stock  
Find more results for NVS
81.06
-0.22 (-0.27%)
After Hours: 81.14 +0.08 (0.10%)
May 23, 4:11PM EDT  
NYSE real-time data - Disclaimer
Currency in USD
Range 80.89 - 81.43
52 week 66.93 - 83.58
Open 81.12
Vol / Avg. 0.00/2.72M
Mkt cap 215.42B
P/E 30.51
Div/yield 2.72/3.35
EPS 2.66
Shares 2.36B
Beta 0.78
Inst. own 12%
Feb 28, 2017
Novartis AG Annual Shareholders Meeting
More events from DailyFinance »    

Key stats and ratios

Q1 (Mar '17) 2016
Net profit margin 14.13% 13.55%
Operating margin 16.31% 16.74%
EBITD margin - 28.27%
Return on average assets 5.10% 5.12%
Return on average equity 9.38% 8.84%
Employees 118,000 -
CDP Score - A-

Address

Lichtstrasse 35
BASEL, 4056
Switzerland
+41-61-3241111 (Phone)
+41-61-3247826 (Fax)

Website links

External links

Analyst Estimates - MarketWatch
SEC Filings - EDGAR Online
Major Holders - MSN Money

Description

Novartis AG is a holding company, which provides healthcare solutions. The Company is engaged in the research, development, manufacturing and marketing of a range of healthcare products led by pharmaceuticals. The Company's segments include Innovative Medicines, Sandoz, Alcon and Corporate activities. Innovative Medicines researches, develops, manufactures, distributes and sells patented prescription medicines to develop health outcomes for patients and healthcare providers. Sandoz develops, manufactures, distributes and sells prescription medicines, as well as pharmaceutical active substances that are not protected by valid and enforceable third-party patents. Alcon researches, develops, manufactures, distributes and sells eye care products. Alcon is a provider of eye care with product offerings in eye care devices and vision care. The Company's range of products includes pharmaceuticals and oncology medicines, generic and biosimilar medicines, and eye care devices.

Officers and directors

Joseph Jimenez Chief Executive Officer, Member of the Executive Committee
Age: 57
Bio & Compensation  - Reuters
Harry Kirsch Chief Financial Officer, Member of the Executive Committee
Age: 51
Bio & Compensation  - Reuters
Michael Ball Chief Executive Officer of Alcon, Member of the Executive Committee
Bio & Compensation  - Reuters
James Bradner M.D. President of the Novartis Institutes for BioMedical Research (NIBR), Member of the Executive Committee
Bio & Compensation  - Reuters
Richard D. Francis Chief Executive Officer of Sandoz Division, Member of the Executive Committee
Age: 48
Bio & Compensation  - Reuters
Paul Hudson Chief Executive Officer of Novartis Pharmaceuticals, Member of the Executive Committee
Bio & Compensation  - Reuters
Bruno Strigini Chief Executive Officer of Novartis Oncology, Member of the Executive Committee
Bio & Compensation  - Reuters
Felix R. Ehrat Ph.D. Group General Counsel, Member of the Executive Committee
Age: 60
Bio & Compensation  - Reuters
Steven Baert Head of Human Resources, Member of the Executive Committee
Age: 42
Bio & Compensation  - Reuters
Vasant Narasimhan M.D. Global Head of Drug Development and Chief Medical Officer for Novartis, Member of the Executive Committee
Bio & Compensation  - Reuters